Why Did AAPL, XERS, ZETA Stocks Jump To 52-Week Highs Today?

• AAPL stock gained about 2% at close after China Renaissance upgraded the company to ‘Buy’ from ‘Hold’ and raised the price target on the company.

• XERS stock climbed more than 4% after Barclays raised the price target on the firm.

• ZETA stock surged more than 7% amid its strong third-quarter earnings results and a wave of analyst price target upgrades.

Shares of Apple Inc. (AAPL), Xeris Biopharma Holdings Inc. (XERS) and Zeta Global Holdings Corp. (ZETA) jumped to 52-week highs on Wednesday amid company tailwinds, strong financial results, and Wall Street optimism.

AAPL stock gained about 2% at close after China Renaissance upgraded the company to ‘Buy’ from ‘Hold’ with a $425 price target.

See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox

XERS stock climbed more than 4% after Barclays raised the price target on the firm.

ZETA stock surged more than 7% amid its strong third-quarter earnings results and a wave of analyst price target upgrades.

Apple Gains From iPhone Duo Demand

AAPL stock jumped to a 52-week high of $355.91, pushing its market capitalization above $5 trillion, on the back of strong quarterly earnings growth, enthusiasm for the foldable iPhone Duo, and a strategic pivot away from massive AI capital expenditures.

The stock also gained from post-election market rotation when investors shifted out of AI stocks and into more traditional technology names amid concerns of a slowdown in AI buildout following a Democratic win.

China Renaissance also upgraded the company to ‘Buy’ from ‘Hold’ with a $425 price target, adding to the company’s optimism. The revised target implies an upside of 19.5% from the stock’s last close.

On Stocktwits, retail sentiment around AAPL stock jumped from ‘neutral’ to ‘bullish’ over 24 hours. Shares of the company have rallied more than 31% in 2026.

Xeris Biopharma Gains Wall Street Thumbs Up

XERS stock reached a 52-week high of $16.57 on Wednesday, putting it on track for a third week of gains amid its strong third quarter (Q3) earnings performance.

The company beat Wall Street estimates with $0.06 earnings per share on $107.2 million of revenue.

Barclays raised the price target on Xeris Biopharma to $18 from $14 and maintained an ‘Overweight’ rating on the shares., citing the company’s “impressive” Q3 results that were driven by Recorlev, which is outperforming on the back of Cushing’s market strength and Xeris’ commercial efforts.

Craig-Hallum analyst Chase Knickerbocker also raised the price target on Xeris Biopharma to $18 from $12 and maintained a ‘Buy’ rating on the shares following its Q3 results. The company also gained an increased target from Oppenheimer.